Efficacy of Fluticasone Furoate Nasal Spray and Levocetirizine in Patients with Japanese Cedar Pollinosis Subjected to an Artificial Exposure Chamber

Overview

Journal J Drug Assess

Date 2016 Aug 19

PMID 27536443

Authors

Kazuhiro Hashiguchi

Sho Kanzaki

Ken-Ichiro Wakabayashi

Nobuaki Tanaka

Kayoko Kawashima

Kiyochika Suematsu

Shoji Tokunaga

Kaoru Ogawa

Kimihiro Okubo

Affiliations

Soon will be listed here.

Abstract

Objective: This study investigated the clinical efficacy of a combination therapy of levocetirizine (LCTZ) and fluticasone furoate nasal spray (FFNS), compared with LCTZ monotherapy, for the suppression of seasonal allergic rhinitis (SAR) symptoms induced in an artificial exposure chamber.

Methods: This study was a single-center, placebo-controlled, randomized, 3-way cross-over comparative study performed in 42 Japanese cedar pollinosis patients. These subjects received (1) LCTZ plus FFNS (combination group), (2) LCTZ plus FFNS placebo (monotherapy group), or (3) LCTZ placebo plus FFNS placebo (placebo group) once on the night prior to exposure, with a 1-week washout period between exposures. Nasal (sneezing, rhinorrhea, nasal congestion, and itchy nose) and ocular (eye itching and tearing) symptoms were recorded every 15 min, and the number of sneezes, nose blowing events, and the amount of nasal secretions were measured during exposure. The primary end-point was the cumulative incidence of SAR symptoms during exposure and the 'ime to occurrence of symptoms'. The secondary end-points were the total nasal symptom score, the ocular symptom score, the amount of nasal discharge, and the number of sneezes and nose blowing events.

Results: At all the measurement points, the lowest cumulative incidences for the nasal symptoms were observed in the combination group, followed by the monotherapy and placebo groups. All the subjects in the placebo group developed nasal symptoms within 2 h after pollen exposure, while three and eight subjects in the monotherapy and combination groups, respectively, did not develop any nasal symptoms during exposure. In addition, combination therapy delayed the onset of symptoms.

Conclusions: The results demonstrated that combination therapy with FFNS and LCTZ significantly suppressed the induced SAR symptoms and delayed the onset of symptoms compared with LCTZ monotherapy and placebo. Although the conditions of the allergen challenge study using an exposure chamber are different from those in real life, combination therapy with FF and LCTZ was confirmed to be an effective treatment for SAR.

References

Horak F, Zieglmayer P, Zieglmayer R, Kavina A, Lemell P . Levocetirizine has a longer duration of action on improving total nasal symptoms score than fexofenadine after single administration. Br J Clin Pharmacol. 2005; 60(1):24-31. PMC: 1884902. DOI: 10.1111/j.1365-2125.2005.02377.x. View

Ratner P, van Bavel J, Martin B, Hampel Jr F, Howland 3rd W, Rogenes P . A comparison of the efficacy of fluticasone propionate aqueous nasal spray and loratadine, alone and in combination, for the treatment of seasonal allergic rhinitis. J Fam Pract. 1998; 47(2):118-25. View

Okubo K, Nakashima M, Miyake N, Komatsubara M, Okuda M . Comparison of fluticasone furoate and fluticasone propionate for the treatment of Japanese cedar pollinosis. Allergy Asthma Proc. 2008; 30(1):84-94. DOI: 10.2500/aap.2009.30.3182. View

Okubo K, Kurono Y, Fujieda S, Ogino S, Uchio E, Odajima H . Japanese guideline for allergic rhinitis. Allergol Int. 2011; 60(2):171-89. DOI: 10.2332/allergolint.11-rai-0334. View

Day J, Briscoe M, Ratz J . Efficacy of levocetirizine compared with montelukast in subjects with ragweed-induced seasonal allergic rhinitis in the Environmental Exposure Unit. Allergy Asthma Proc. 2008; 29(3):304-12. DOI: 10.2500/aap.2008.29.3109. View

Rodrigo G, Yanez A . The role of antileukotriene therapy in seasonal allergic rhinitis: a systematic review of randomized trials. Ann Allergy Asthma Immunol. 2006; 96(6):779-86. DOI: 10.1016/S1081-1206(10)61339-7. View

Kaiser H, Naclerio R, Given J, Toler T, Ellsworth A, Philpot E . Fluticasone furoate nasal spray: a single treatment option for the symptoms of seasonal allergic rhinitis. J Allergy Clin Immunol. 2007; 119(6):1430-7. DOI: 10.1016/j.jaci.2007.02.022. View

Yamada T, Yamamoto H, Kubo S, Sakashita M, Tokunaga T, Susuki D . Efficacy of mometasone furoate nasal spray for nasal symptoms, quality of life, rhinitis-disturbed sleep, and nasal nitric oxide in patients with perennial allergic rhinitis. Allergy Asthma Proc. 2012; 33(2):e9-16. DOI: 10.2500/aap.2012.33.3509. View

Nielsen L, Dahl R . Comparison of intranasal corticosteroids and antihistamines in allergic rhinitis: a review of randomized, controlled trials. Am J Respir Med. 2004; 2(1):55-65. DOI: 10.1007/BF03256639. View

10.

Patou J, De Smedt H, Van Cauwenberge P, Bachert C . Pathophysiology of nasal obstruction and meta-analysis of early and late effects of levocetirizine. Clin Exp Allergy. 2006; 36(8):972-81. DOI: 10.1111/j.1365-2222.2006.02544.x. View

11.

Ciprandi G, Cirillo I, Vizzaccaro A, Tosca M . Levocetirizine improves nasal obstruction and modulates cytokine pattern in patients with seasonal allergic rhinitis: a pilot study. Clin Exp Allergy. 2004; 34(6):958-64. DOI: 10.1111/j.1365-2222.2004.01960.x. View

12.

Navarro A, Valero A, Rosales M, Mullol J . Clinical use of oral antihistamines and intranasal corticosteroids in patients with allergic rhinitis. J Investig Allergol Clin Immunol. 2011; 21(5):363-9. View

13.

Okano M . Mechanisms and clinical implications of glucocorticosteroids in the treatment of allergic rhinitis. Clin Exp Immunol. 2009; 158(2):164-73. PMC: 2768806. DOI: 10.1111/j.1365-2249.2009.04010.x. View

14.

Schatz M . A survey of the burden of allergic rhinitis in the USA. Allergy. 2007; 62 Suppl 85:9-16. DOI: 10.1111/j.1398-9995.2007.01548.x. View

15.

Allen A, Down G, Newland A, Reynard K, Rousell V, Salmon E . Absolute bioavailability of intranasal fluticasone furoate in healthy subjects. Clin Ther. 2007; 29(7):1415-20. DOI: 10.1016/j.clinthera.2007.07.028. View

16.

Stubner P, Zieglmayer R, Horak F . A direct comparison of the efficacy of antihistamines in SAR and PAR: randomised, placebo-controlled studies with levocetirizine and loratadine using an environmental exposure unit - the Vienna Challenge Chamber (VCC). Curr Med Res Opin. 2004; 20(6):891-902. DOI: 10.1185/030079904125003700. View

17.

Day J, Briscoe M, Rafeiro E, Ratz J . Comparative clinical efficacy, onset and duration of action of levocetirizine and desloratadine for symptoms of seasonal allergic rhinitis in subjects evaluated in the Environmental Exposure Unit (EEU). Int J Clin Pract. 2004; 58(2):109-18. DOI: 10.1111/j.1368-5031.2004.0117.x. View

18.

Takahashi G, Matsuzaki Z, Nakayama T, Masuyama K . Patterns of drug prescription for Japanese cedar pollinosis using a clinical vignette questionnaire. Allergol Int. 2008; 57(4):405-11. DOI: 10.2332/allergolint.O-08-534. View

19.

Patel P, Patel D . Efficacy comparison of levocetirizine vs montelukast in ragweed sensitized patients. Ann Allergy Asthma Immunol. 2008; 101(3):287-94. DOI: 10.1016/S1081-1206(10)60494-2. View

20.

Day J, Briscoe M, Rafeiro E, Ellis A, Pettersson E, AKERLUND A . Onset of action of intranasal budesonide (Rhinocort aqua) in seasonal allergic rhinitis studied in a controlled exposure model. J Allergy Clin Immunol. 2000; 105(3):489-94. DOI: 10.1067/mai.2000.104550. View